JP2017169559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017169559A5 JP2017169559A5 JP2017037848A JP2017037848A JP2017169559A5 JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5 JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cell
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 101150074155 DHFR gene Proteins 0.000 claims 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 1
- 108020001096 dihydrofolate reductase Proteins 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492617P | 2011-06-02 | 2011-06-02 | |
| US61/492,617 | 2011-06-02 | ||
| US201161498266P | 2011-06-17 | 2011-06-17 | |
| US61/498,266 | 2011-06-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513732A Division JP6104897B2 (ja) | 2011-06-02 | 2012-06-01 | Ｆｃレセプター結合タンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018085040A Division JP6638018B2 (ja) | 2011-06-02 | 2018-04-26 | Ｆｃレセプター結合タンパク質 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017169559A JP2017169559A (ja) | 2017-09-28 |
| JP2017169559A5 true JP2017169559A5 (enExample) | 2017-12-07 |
| JP6334763B2 JP6334763B2 (ja) | 2018-05-30 |
| JP6334763B6 JP6334763B6 (ja) | 2018-07-11 |
Family
ID=47259886
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513732A Active JP6104897B2 (ja) | 2011-06-02 | 2012-06-01 | Ｆｃレセプター結合タンパク質 |
| JP2017037848A Active JP6334763B6 (ja) | 2011-06-02 | 2017-03-01 | Ｆｃレセプター結合タンパク質 |
| JP2018085040A Active JP6638018B2 (ja) | 2011-06-02 | 2018-04-26 | Ｆｃレセプター結合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513732A Active JP6104897B2 (ja) | 2011-06-02 | 2012-06-01 | Ｆｃレセプター結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018085040A Active JP6638018B2 (ja) | 2011-06-02 | 2018-04-26 | Ｆｃレセプター結合タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US9359438B2 (enExample) |
| EP (2) | EP2714084B1 (enExample) |
| JP (3) | JP6104897B2 (enExample) |
| KR (1) | KR102014554B1 (enExample) |
| CN (2) | CN103619353B (enExample) |
| AU (2) | AU2012262007B2 (enExample) |
| BR (1) | BR112013030352B1 (enExample) |
| CA (1) | CA2837527C (enExample) |
| ES (1) | ES2748583T3 (enExample) |
| IL (1) | IL229618B (enExample) |
| MX (1) | MX343659B (enExample) |
| PH (1) | PH12013502378A1 (enExample) |
| SG (2) | SG10201604493TA (enExample) |
| WO (1) | WO2012167039A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3131470A1 (en) * | 2008-04-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| CN103619353B (zh) | 2011-06-02 | 2016-01-06 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201320066D0 (en) * | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| ES2909014T3 (es) * | 2013-11-26 | 2022-05-04 | Brigham & Womens Hospital Inc | Composiciones y métodos para modular una respuesta inmunitaria |
| NZ737666A (en) | 2014-04-30 | 2018-10-26 | Hanall Biopharma Co Ltd | Antibody binding to fcrn for treating autoimmune diseases |
| US10336825B2 (en) | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
| SG10202007232WA (en) * | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| KR20190015704A (ko) * | 2016-04-25 | 2019-02-14 | 신티뮨, 인크. | 인간화된 친화성 성숙 항-fcrn 항체 |
| CA3032415A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| KR20240055164A (ko) | 2016-12-01 | 2024-04-26 | 사빅 글로벌 테크놀러지스 비.브이. | 하이브리드 복합 뒷문 |
| RU2020100880A (ru) * | 2017-06-15 | 2021-07-15 | Юсб Биофарма Срл | Способ лечения иммунной тромбоцитопении |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| AU2018386193B2 (en) * | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| EP3823978A4 (en) * | 2018-07-20 | 2022-12-14 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
| WO2021012176A1 (en) * | 2019-07-23 | 2021-01-28 | Shanghaitech University | Asic1 channel antagonist antibody |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| CA3183153A1 (en) | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| KR20250018382A (ko) | 2022-05-30 | 2025-02-05 | 한올바이오파마주식회사 | 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편 |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| CN119490588A (zh) * | 2024-10-17 | 2025-02-21 | 广州康盛生物科技股份有限公司 | 一种抗人FcRn的VHH抗体及其应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
| DE2901218A1 (de) | 1979-01-13 | 1980-07-17 | Byk Gulden Lomberg Chem Fab | Ung von theophyllin |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0317156B2 (en) | 1987-11-09 | 1997-11-12 | Becton, Dickinson and Company | Method for analysis of hematopoietic cells in a sample |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5030002A (en) | 1989-08-11 | 1991-07-09 | Becton, Dickinson And Company | Method and apparatus for sorting particles with a moving catcher tube |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| IE76732B1 (en) | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
| US5179107A (en) | 1990-09-07 | 1993-01-12 | Schering Corporation | Antiviral quinolinone compounds |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| CA2087413A1 (en) | 1992-01-17 | 1993-07-18 | Joseph R. Lakowicz | Fluorescent energy transfer immunoassay |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| PT971946E (pt) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| US6960178B2 (en) | 2000-02-02 | 2005-11-01 | Xepmed, Inc. | Apparatus for enhanced plasmapheresis and methods thereof |
| US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| ES2405551T3 (es) | 2001-10-01 | 2013-05-31 | Dyax Corporation | Vectores de presentación eucariotas multicatenarios y usos de los mismos |
| US20040005709A1 (en) | 2001-10-24 | 2004-01-08 | Hoogenboom Henricus Renerus Jacobus Mattheus | Hybridization control of sequence variation |
| CA2478169C (en) | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| JP2007501847A (ja) * | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| WO2006118772A2 (en) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
| CA2637929A1 (en) * | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| US20070181136A1 (en) | 2006-02-08 | 2007-08-09 | Gelb Michael L | Oral appliance |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| CA3131470A1 (en) | 2008-04-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| US8537763B2 (en) | 2008-06-30 | 2013-09-17 | Motorola Mobility Llc | Frame allocation to support legacy wireless communication protocols on uplink transmission |
| US8993728B2 (en) * | 2008-07-16 | 2015-03-31 | Medical And Biological Laboratories Co., Ltd. | Anti-human CLCP1 antibody and use thereof |
| TW201029662A (en) * | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| WO2010107110A1 (ja) * | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| CN103619353B (zh) | 2011-06-02 | 2016-01-06 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
| BR112019025583A2 (pt) | 2017-06-05 | 2020-06-16 | Janssen Biotech, Inc. | Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
-
2012
- 2012-06-01 CN CN201280031902.0A patent/CN103619353B/zh active Active
- 2012-06-01 AU AU2012262007A patent/AU2012262007B2/en active Active
- 2012-06-01 CN CN201510926183.4A patent/CN105622754B/zh active Active
- 2012-06-01 ES ES12793948T patent/ES2748583T3/es active Active
- 2012-06-01 PH PH1/2013/502378A patent/PH12013502378A1/en unknown
- 2012-06-01 SG SG10201604493TA patent/SG10201604493TA/en unknown
- 2012-06-01 EP EP12793948.6A patent/EP2714084B1/en active Active
- 2012-06-01 SG SG2013085204A patent/SG195025A1/en unknown
- 2012-06-01 KR KR1020137034618A patent/KR102014554B1/ko active Active
- 2012-06-01 MX MX2013013832A patent/MX343659B/es active IP Right Grant
- 2012-06-01 US US14/122,880 patent/US9359438B2/en active Active
- 2012-06-01 JP JP2014513732A patent/JP6104897B2/ja active Active
- 2012-06-01 BR BR112013030352-2A patent/BR112013030352B1/pt active IP Right Grant
- 2012-06-01 EP EP15167896.8A patent/EP2966089B1/en active Active
- 2012-06-01 CA CA2837527A patent/CA2837527C/en active Active
- 2012-06-01 WO PCT/US2012/040409 patent/WO2012167039A1/en not_active Ceased
-
2013
- 2013-11-25 IL IL229618A patent/IL229618B/en active IP Right Grant
-
2016
- 2016-04-27 US US15/139,784 patent/US9862768B2/en active Active
-
2017
- 2017-03-01 JP JP2017037848A patent/JP6334763B6/ja active Active
- 2017-09-21 AU AU2017232160A patent/AU2017232160B2/en active Active
- 2017-12-04 US US15/830,998 patent/US10479834B2/en active Active
-
2018
- 2018-04-26 JP JP2018085040A patent/JP6638018B2/ja active Active
-
2019
- 2019-10-07 US US16/594,218 patent/US11014988B2/en active Active
-
2021
- 2021-03-17 US US17/203,816 patent/US11739152B2/en active Active
-
2023
- 2023-07-06 US US18/347,626 patent/US12454575B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017169559A5 (enExample) | ||
| US20230242651A1 (en) | Stable antibody variable domain framework combinations | |
| JP2020519308A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2020504101A5 (enExample) | ||
| KR102286053B1 (ko) | 신규한 항체 기본구조 | |
| RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
| US20220403028A1 (en) | Novel anti-cd3 antibodies | |
| HRP20201993T1 (hr) | Protutijela protiv pd-1 | |
| RU2011153932A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ | |
| JP2013545455A5 (enExample) | ||
| JP2019504617A5 (enExample) | ||
| FI3561057T3 (fi) | Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä | |
| JP2020524510A5 (enExample) | ||
| JP2012514997A5 (enExample) | ||
| RU2013119957A (ru) | Человеческие антитела к онкостатину м и способы их применения | |
| RU2012122203A (ru) | Композиции и способы для лечения восполительных нарушений | |
| US20200325214A1 (en) | Novel anti-hsa antibodies | |
| WO2023193732A1 (zh) | 一种抗ccr8抗体或其抗原结合片段 | |
| JP2016518333A5 (enExample) | ||
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
| JP2022528387A (ja) | アビド結合多重特異性抗体を作製する方法 | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| US20150093783A1 (en) | Humanized antibodies to ca215 | |
| JP2016540504A5 (enExample) |